We are pleased to see Base Therapeutics, GenEditBio, and Health2Sync featured on the all-new Forbes Asia 100 To Watch list. The annual list spotlights 100 small companies and startups with significant growth potential across the Asia-Pacific region.

- Base Therapeutics is pushing the boundaries of biotechnology with cutting-edge gene editing solutions aimed at tackling some of the world’s most challenging diseases.
- GenEditBio is advancing next-generation therapies with precision genetic editing, offering hope for patients worldwide.
- Health2Sync  is transforming digital healthcare with AI-driven tools that empower people to better manage chronic conditions and improve everyday wellness.

We are so happy to see Base Therapeutics, GenEditBio, and Health2Sync leveraging advanced technology to create better health solutions for all. Their recognition on the Forbes Asia 100 to Watch list is a strong testament to their vision, resilience, and impact.

At AEF, we are proud to support these entrepreneurs as they continue to grow, inspire, and lead the way in building a healthier and more sustainable future.